National Institutes of Health: Scleroderma, Systemic trials

The registry lists 14 Scleroderma, Systemic studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 2Phase 2 5Phase 3 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingNCT03816345Phase 1
• COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedNCT05000216Phase 2Results posted
• Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)CompletedNCT01086540Phase 2Results posted
• Scleroderma: Cyclophosphamide or TransplantationCompletedNCT00114530Phase 2/3Results posted
• SCOT Scleroderma Treatment Alternative Registry (STAR Registry)CompletedNCT00860548
• Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate MofetilCompletedNCT00853788
• Scleroderma RegistryCompletedNCT00074568
• Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma PatientsTerminatedNCT00040651Phase 1
• Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic SclerosisStatus unknownNCT00006393
• Oral Type I Collagen for Relieving SclerodermaCompletedNCT00005675Phase 2
• Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung DiseasesCompletedNCT00005317
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic SclerosisCompletedNCT00004786Phase 3
• Phase II Study of Recombinant Relaxin for Progressive Systemic SclerosisCompletedNCT00004380Phase 2
• Study of Silicone-Associated Connective Tissue DiseasesCompletedNCT00001330